Kempharm Stock Stock News Today

KMPH -  USA Stock  

USD 10.99  0.23  2.14%

Kempharm Stock News module provides quick insight into current market opportunities from investing in Kempharm. Use historical and current headlines to determine the investment entry and exit points. Many technical investors use Kempharm stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Please see Kempharm Hype Analysis, Kempharm Correlation and Kempharm Performance.

Search Today's Stock News 

 
Refresh
Kempharm stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Kempharm daily returns and investor perception about the current pice of Kempharm as well as its diversification or hedging effects on your existing portfolios.
over a week ago at www.cmlviz.com         
KMPH KemPharm Announces U.S. Launch Of Innovative ADHD Treatment Azstarys By Corium - CML News
C
over a week ago at marketingsentinel.com         
Boom Or Bust What Are KemPharm Inc.s Future Prospects - Marketing Sentinel
M
over two weeks ago at www.equities.com         
KemPharm Inc gains 2.7010 percent for July 09 - Equities.com
Equities News
over three weeks ago at www.equities.com         
KemPharm Inc falls -2.7050 percent for July 02 - Equities.com
Equities News
over a month ago at seekingalpha.com         
KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety - Seeking Alpha
seekingalpha News
over a month ago at www.macroaxis.com         
Purchase by Clifton R Laduane of tradable shares of Kempharm
Macroaxis News
over a month ago at www.macroaxis.com         
Acquisition by Matthew Plooster of 15000 shares of Kempharm subject to Rule 16b-3
Macroaxis News
over a month ago at www.fool.com         
Why KemPharm Stock Sank Today - The Motley Fool
fool News
over a month ago at www.globenewswire.com         
KemPharm Issues Letter to Shareholders - GlobeNewswire
GN
over a month ago at www.macroaxis.com         
Kempharm exotic insider transaction detected
Macroaxis News
over a month ago at www.benzinga.com         
Why This News Could Help KemPharm Stock Break Out A Technical Analysis - Benzinga - Benzinga
benzinga news
over a month ago at finance.yahoo.com         
KemPharm to be Added to Russell 2000 and Russell 3000 Indexes Effective June 28, 2021 - Yahoo Financ...
Yahoo News
over a month ago at www.equities.com         
KemPharm Inc gains 1.9820 percent for June 04 - Equities.com
Equities News
over two months ago at www.macroaxis.com         
Purchase by Clifton R Laduane of 150 shares of Kempharm
Macroaxis News
over two months ago at www.equities.com         
Kempharm Inc falls 1.5 percent for May 26 - Equities.com
Equities News
There is far too much social signal, news, headlines, and media speculation about Kempharm that is available to investors today. That information is available publicly through Kempharm media outlets and privately through word of mouth or via Kempharm internal channels. However, regardless of the origin, that massive amount of Kempharm data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kempharm news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kempharm relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kempharm's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kempharm alpha.

Kempharm Performance against DOW

 Price Growth (%)  
      Timeline 
1
EPS Reported05/13/2021
2
Purchase by Braun Samuel J of 10000 shares of KemPharm05/17/2021
3
Purchase by Clifton R Laduane of 150 shares of Kempharm05/27/2021
4
KemPharm Inc gains 1.9820 percent for June 04 - Equities.com06/04/2021
5
Kempharm exotic insider transaction detected06/14/2021
6
Financial Statements06/16/2021
7
Acquisition by Matthew Plooster of 15000 shares of Kempharm ...06/21/2021
8
Financial Statements06/23/2021
9
Purchase by Clifton R Laduane of tradable shares of Kempharm06/24/2021
10
KemPharm Inc falls -2.7050 percent for July 02 - Equities.co...07/02/2021
11
KMPH KemPharm Announces U.S. Launch Of Innovative ADHD Treat...07/21/2021
Please see Kempharm Hype Analysis, Kempharm Correlation and Kempharm Performance. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fund Screener module to find activelly-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.